Jury Favors AbbVie in the Fifth TRT Bellwether Trial
Jury Favors AbbVie in the Fifth TRT Bellwether Trial
Introduction
AbbVie Inc. won yet another lawsuit on June 14 over claims that its AndroGel caused a man's deep vein thrombosis (DVT). This is the fifth testosterone replacement therapy bellwether trial, which began on June 5, in the Illinois State Court for a plaintiff.
The plaintiff filed a lawsuit in 2014 after suffering from DVT in April 2013 and in late 2015. He blamed Androgel use for both incidents. The federal jury dismissed the plaintiff's allegation that AndroGel's use led to his blood clot. Last month, a plaintiff and his wife lost to AbbVie, as the jury stated that the drug was not responsible for his bilateral pulmonary embolism that occurred in February 2008.
Testosterone Replacement Therapy lawsuits are centralized before U.S. District Judge Matthew Kennelly in the Northern District of Illinois as a part of federal multidistrict litigation (MDL No. 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation).
Comments
Latest News
Study Links Roundup Chemical to Long-Term Brain Damage
Categories: Roundup
A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Categories: Zimmer Hip/Knee Replacement
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
Categories: Hernia Mesh
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…